Cellosaurus logo
expasy logo

Cellosaurus PLC/PRF/5 (CVCL_0485)

[Text version]
Cell line name PLC/PRF/5
Synonyms PLC-PRF-5; PLC PRF 5; PLC/PRF5; PLCPRF5; PLC-8024; PLC8024; PLC; Alexander cells; Alexander; Primary Liver Carcinoma/Poliomyelitis Research Foundation/5
Accession CVCL_0485
Secondary accession CVCL_6714
Resource Identification Initiative To cite this cell line use: PLC/PRF/5 (RRID:CVCL_0485)
Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: JFCR45 cancer cell line panel.
Part of: Liver Cancer Model Repository (LIMORE).
Part of: MD Anderson Cell Lines Project.
Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8024.
Population: African; Shangaan.
Virology: Contains at least 7 copies of integrated hepatitis B virus (HBV) genomes. Secretes hepatitis virus B surface antigen (HBsAg).
Virology: Susceptible to infection by adenovirus types 40 (Ad40) and 41 (Ad41) (PubMed=1317878).
Doubling time: 35-40 hours (PubMed=63998); 20.05-28.76 hours (PubMed=31378681).
Karyotypic information: Has lost chromosome Y.
Transformant: NCBI_TaxID; 10407; Hepatitis B virus (HBV).
Omics: Deep exome analysis.
Omics: Genome sequenced.
Omics: miRNA expression profiling.
Omics: Protein expression by reverse-phase protein arrays.
Omics: Secretome proteome analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
Caution: Often called PLC8024 in Chinese literature probably because of a concatenation between PLC/PRF/5 and ATCC-8024.
Misspelling: PCL/PRF/5; Cosmic=873402.
Derived from site: In situ; Liver; UBERON=UBERON_0002107.
Sequence variations
  • Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg112Gly (c.334C>G) (p.Pro126Arg, c.377C>G); ClinVar=VCV000233484; Zygosity=Homozygous (PubMed=31378681; DepMap=ACH-001318).
  • Mutation; HGNC; 11998; TP53; Simple; p.Arg249Ser (c.747G>T); ClinVar=VCV000012352; Zygosity=Homozygous (PubMed=8224613; PubMed=8389256; DepMap=ACH-001318).
  • Mutation; HGNC; 12363; TSC2; Simple; p.Asn1651Ser (c.4952A>G); ClinVar=VCV000049335; Zygosity=Homozygous (DepMap=ACH-001318).
HLA typing Source: PubMed=9178645
Class I
HLA-AA*33:02
HLA-BB*42:01,53:01
HLA-CC*04:01,17:01

Source: PubMed=26589293
Class I
HLA-AA*03:01,33:03
HLA-BB*42:02,53:01
HLA-CC*04:01,17:01
Class II
HLA-DQDQB1*06:07,06:07
HLA-DRDRB1*11:73,11:73

Source: CLS=300315
Class I
HLA-AA*03:01:01,09:03:01
HLA-BB*42:02:01,53:01:01
HLA-CC*04:01,04
Class II
HLA-DPDPB1*17,18:01
HLA-DQDQA1*01:03:01,04:01:02
DQB1*03:19:01,06:03:01
HLA-DRDRB1*08:04:01,13:01:01
Genome ancestry Source: PubMed=30894373

Origin% genome
African95.79
Native American0
East Asian, North1.61
East Asian, South0
South Asian0
European, North0
European, South2.59
Disease Adult hepatocellular carcinoma (NCIt: C7956)
Adult hepatocellular carcinoma (ORDO: Orphanet_210159)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_A8RU (N1380)CVCL_B449 (NPLC/PRF/5)CVCL_LJ87 (PLC/PRF/5 Luciferase/GFP)
CVCL_XB32 (PLC/PRF/5-Cas9-705)CVCL_XB33 (PLC/PRF/5-Cas9-706)CVCL_XB34 (PLC/PRF/5-Cas9-707)
CVCL_XB35 (PLC/PRF/5-Cas9-708)CVCL_XB36 (PLC/PRF/5-Cas9-709)CVCL_XB37 (PLC/PRF/5-Cas9-710)
CVCL_XB38 (PLC/PRF/5-Cas9-711)CVCL_XB39 (PLC/PRF/5-Cas9-712)CVCL_XB40 (PLC/PRF/5-Cas9-713)
CVCL_XB41 (PLC/PRF/5-Cas9-714)CVCL_XB42 (PLC/PRF/5-Cas9-715)CVCL_C9DF (PLC/PRF/5/Cas9-hyg)
Sex of cell Male
Age at sampling 24Y
Category Cancer cell line
STR profile Source(s): ATCC=CRL-8024; CCRID; CLS=300315; ECACC=85061113; JCRB=IFO50069; JCRB=JCRB0406; KCLB=28024; PubMed=25877200; PubMed=31378681

Markers:
AmelogeninX
CSF1PO10
D1S165614
D2S44112,14
D2S133819 (CLS=300315; PubMed=25877200)
19,22 (ATCC=CRL-8024; CCRID)
D3S135815
D5S81812
D6S104313,21
D7S8209,11
D8S117913,16
D12S39115,20 (CCRID)
20 (CLS=300315; PubMed=25877200)
D13S31711,12
D16S53913
D18S5117
D19S43311,13
D21S1130,33.2
FGA19.2,25
Penta D6,10
Penta E10,16
TH017,8 (CLS=300315; ECACC=85061113; JCRB=IFO50069; JCRB=JCRB0406; KCLB=28024; PubMed=25877200; PubMed=31378681)
8 (ATCC=CRL-8024; CCRID)
TPOX8
vWA15,16

Run an STR similarity search on this cell line
Web pages https://lccl.zucmanlab.com/hcc/cellLines/PLC.PRF5
https://tcpaportal.org/mclp/
Publications

PubMed=63998
Alexander J.J., Bey E.M., Geddes E.W., Lecatsas G.
Establishment of a continuously growing cell line from primary carcinoma of the liver.
S. Afr. Med. J. 50:2124-2128(1976)

PubMed=184551
Alexander J.J., Bey E.M., Whitcutt J.M., Gear J.H.S.
Adaptation of cells derived from human malignant tumours to growth in vitro.
S. Afr. J. Med. Sci. 41:89-98(1976)

PubMed=187208; DOI=10.1038/bjc.1976.205; PMCID=PMC2025201
MacNab G.M., Alexander J.J., Lecatsas G., Bey E.M., Urbanowicz J.M.
Hepatitis B surface antigen produced by a human hepatoma cell line.
Br. J. Cancer 34:509-515(1976)

PubMed=6160110; DOI=10.1128/IAI.30.2.607-611.1980; PMCID=PMC551353
Daemer R.J., Feinstone S.M., Alexander J.J., Tully J.G., London W.T., Wong D.C., Purcell R.H.
PLC/PRF/5 (Alexander) hepatoma cell line: further characterization and studies of infectivity.
Infect. Immun. 30:607-611(1980)

PubMed=6248960; DOI=10.1126/science.6248960
Knowles B.B., Howe C.C., Aden D.P.
Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen.
Science 209:497-499(1980)

PubMed=6268737; DOI=10.1099/0022-1317-53-1-105
Oefinger P.E., Bronson D.L., Dreesman G.R.
Induction of hepatitis B surface antigen in human hepatoma-derived cell lines.
J. Gen. Virol. 53:105-113(1981)

PubMed=6275024; DOI=10.1099/0022-1317-57-1-95
Koshy R., Maupas P., Muller R., Hofschneider P.H.
Detection of hepatitis B virus-specific DNA in the genomes of human hepatocellular carcinoma and liver cirrhosis tissues.
J. Gen. Virol. 57:95-102(1981)

PubMed=6288577; DOI=10.1002/ijc.2910300106
Simon D., Aden D.P., Knowles B.B.
Chromosomes of human hepatoma cell lines.
Int. J. Cancer 30:27-33(1982)

PubMed=6889516; DOI=10.1016/0277-5379(82)90010-4
Sattler F.R., Paolucci S., Kreider J.W., Ladda R.L.
A human hepatoma cell line (PCL/PRF/5) produces lung metastases and secretes HBsAg in nude mice.
Eur. J. Cancer Clin. Oncol. 18:381-389(1982)

PubMed=6225510; DOI=10.1007/BF00199161; PMCID=PMC11039258
Keong A., Rabson A.R.
Supernatant derived from a human hepatocellular carcinoma cell line (PLC/PRF/5) activates a population of T-suppressor cells.
Cancer Immunol. Immunother. 15:178-182(1983)

PubMed=6555060; DOI=10.1007/BF00199162; PMCID=PMC11039064
Keong A., Herman J., Rabson A.R.
Supernatant derived from a human hepatocellular carcinoma cell line (PLC/PRF/5) depresses natural killer (NK) cell activity.
Cancer Immunol. Immunother. 15:183-187(1983)

PubMed=2414854
Aspinall S., Alexander J.J.
Hepatitis B virus gene expression in two cell lines, one derived from a natural human infection, the other experimentally infected in vitro.
S. Afr. Med. J. 68:751-754(1985)

PubMed=2992761; DOI=10.1016/0165-4608(85)90033-0
Pinto M.R., Bey E.M., Bernstein R.
The PLC/PRF/5 human hepatoma cell line. I. Reevaluation of the karyotype.
Cancer Genet. Cytogenet. 18:11-18(1985)

PubMed=2992762; DOI=10.1016/0165-4608(85)90034-2
Bowcock A.M., Pinto M.R., Bey E.M., Kuyl J.M., Dusheiko G.M., Bernstein R.
The PLC/PRF/5 human hepatoma cell line. II. Chromosomal assignment of hepatitis B virus integration sites.
Cancer Genet. Cytogenet. 18:19-26(1985)

PubMed=3023526; DOI=10.1099/0022-1317-67-11-2315
Aspinall S., Alexander J.J., Bos P.
Comparative expression of hepatitis B virus antigens in several cell model systems.
J. Gen. Virol. 67:2315-2323(1986)

DOI=10.1007/978-4-431-68349-0_4
Alexander J.J.
Human hepatoma cell lines.
(In book chapter) Neoplasms of the liver; Okuda K., Ishak K.G. (eds.); pp.47-56; Springer; Tokyo; Japan (1987)

PubMed=2439335; DOI=10.1111/j.1432-1033.1987.tb11497.x
Vincent C., Marceau M., Blangarin P., Bouic P., Madjar J.-J., Revillard J.-P.
Purification of alpha 1-microglobulin produced by human hepatoma cell lines. Biochemical characterization and comparison with alpha 1-microglobulin synthesized by human hepatocytes.
Eur. J. Biochem. 165:699-704(1987)

PubMed=2542205; DOI=10.1111/j.1349-7006.1989.tb02290.x; PMCID=PMC5917712
Tsuda H., Hirohashi S., Shimosato Y., Ino Y., Yoshida T., Terada M.
Low incidence of point mutation of c-Ki-ras and N-ras oncogenes in human hepatocellular carcinoma.
Jpn. J. Cancer Res. 80:196-199(1989)

PubMed=1661347; DOI=10.2302/kjm.40.139
Saito H., Morizane T., Watanabe T., Kagawa T., Miyaguchi S., Kumagai N., Tsuchimoto K., Tsuchiya M.
Proto-oncogene expression in three human hepatoma cell lines, HCC-M, HCC-T and PLC/PRF/5.
Keio J. Med. 40:139-145(1991)

PubMed=1317878; DOI=10.1016/0166-0934(92)90047-h
Grabow W.O.K., Puttergill D.L., Bosch A.
Propagation of adenovirus types 40 and 41 in the PLC/PRF/5 primary liver carcinoma cell line.
J. Virol. Methods 37:201-207(1992)

PubMed=8224613; DOI=10.1096/fasebj.7.14.8224613
Puisieux A., Galvin K., Troalen F., Bressac B., Marcais C., Galun E., Ponchel F., Yakicier C., Ji J.-W., Ozturk M.
Retinoblastoma and p53 tumor suppressor genes in human hepatoma cell lines.
FASEB J. 7:1407-1413(1993)

PubMed=8389256; DOI=10.1093/carcin/14.5.987
Hsu I.C., Tokiwa T., Bennett W., Metcalf R.A., Welsh J.A., Sun T., Harris C.C.
p53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines.
Carcinogenesis 14:987-992(1993)

PubMed=7874267; DOI=10.1007/BF02349278
Ikuta S., Itoh F., Hinoda Y., Toyota M., Makiguchi Y., Imai K., Yachi A.
Expression of cytoskeletal-associated protein tyrosine phosphatase PTPH1 mRNA in human hepatocellular carcinoma.
J. Gastroenterol. 29:727-732(1994)

PubMed=8050184; DOI=10.1111/j.1365-2249.1994.tb06089.x; PMCID=PMC1534706
Wadee A.A., Paterson A., Coplan K.A., Reddy S.G.
HLA expression in hepatocellular carcinoma cell lines.
Clin. Exp. Immunol. 97:328-333(1994)

PubMed=8835345; DOI=10.1002/(SICI)1096-9071(199602)48:2<133::AID-JMV3>3.0.CO;2-A
Tsuboi S., Nagamori S., Miyazaki M., Mihara K., Fukaya K.-i., Teruya K., Kosaka T., Tsuji T., Namba M.
Persistence of hepatitis C virus RNA in established human hepatocellular carcinoma cell lines.
J. Med. Virol. 48:133-140(1996)

DOI=10.11418/jtca1981.16.3_173
Mihara K., Miyazaki M., Fushimi K., Tsuji T., Inoue Y., Fukaya K.-i., Ohashi R., Namba M.
The p53 gene status and other cellular characteristics of human cell lines maintained in our laboratory.
Tissue Cult. Res. Commun. 16:173-178(1997)

PubMed=9023415; DOI=10.1006/cimm.1996.1062
Seki N., Hoshino T., Kikuchi M., Hayashi A., Itoh K.
HLA-A locus-restricted and tumor-specific CTLs in tumor-infiltrating lymphocytes of patients with non-small cell lung cancer.
Cell. Immunol. 175:101-110(1997)

PubMed=9178645; DOI=10.1006/cimm.1997.1108
Nakao M., Sata M., Saitsu H., Yutani S., Kawamoto M., Kojiro M., Itoh K.
CD4+ hepatic cancer-specific cytotoxic T lymphocytes in patients with hepatocellular carcinoma.
Cell. Immunol. 177:176-181(1997)

PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D
Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T., Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M., Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.
Screening the p53 status of human cell lines using a yeast functional assay.
Mol. Carcinog. 19:243-253(1997)

PubMed=9359923; DOI=10.18926/AMO/30789
Mihara K., Miyazaki M., Kondo T., Fushimi K., Tsuji T., Inoue Y., Fukaya K.-i., Ishioka C., Namba M.
Yeast functional assay of the p53 gene status in human cell lines maintained in our laboratory.
Acta Med. Okayama 51:261-265(1997)

PubMed=10523694; DOI=10.3892/or.6.6.1267
Gao C., Ohashi R., Pu H., Inoue Y., Tsuji T., Miyazaki M., Namba M.
Yeast functional assay of the p53 gene status in 11 cell lines and 26 surgical specimens of human hepatocellular carcinoma.
Oncol. Rep. 6:1267-1271(1999)

PubMed=11050057; DOI=10.1053/jhep.2000.19349
Wong N., Lai P., Pang E., Leung T.W.-T., Lau J.W.-Y., Johnson P.J.
A comprehensive karyotypic study on human hepatocellular carcinoma by spectral karyotyping.
Hepatology 32:1060-1068(2000)

PubMed=12029633; DOI=10.1053/jhep.2002.33683
Yasui K., Arii S., Zhao C., Imoto I., Ueda M., Nagai H., Emi M., Inazawa J.
TFDP1, CUL4A, and CDC16 identified as targets for amplification at 13q34 in hepatocellular carcinomas.
Hepatology 35:1476-1484(2002)

PubMed=15767549; DOI=10.1158/1535-7163.MCT-04-0234
Nakatsu N., Yoshida Y., Yamazaki K., Nakamura T., Dan S., Fukui Y., Yamori T.
Chemosensitivity profile of cancer cell lines and identification of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arrays.
Mol. Cancer Ther. 4:399-412(2005)

PubMed=20069059; DOI=10.1155/2010/437143; PMCID=PMC2801507
Srisomsap C., Sawangareetrakul P., Subhasitanont P., Chokchaichamnankit D., Chiablaem K., Bhudhisawasdi V., Wongkham S., Svasti J.
Proteomic studies of cholangiocarcinoma and hepatocellular carcinoma cell secretomes.
J. Biomed. Biotechnol. 2010:437143.1-437143.18(2010)

PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113
Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=23505090; DOI=10.1002/hep.26402
Wang K., Lim H.Y., Shi S., Lee J., Deng S.-B., Xie T., Zhu Z., Wang Y.-L., Pocalyko D., Yang W.J., Rejto P.A., Mao M., Park C.-K., Xu J.-C.
Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma.
Hepatology 58:706-717(2013)

PubMed=23887712; DOI=10.1038/ncomms3218; PMCID=PMC3731665
Nault J.-C., Mallet M., Pilati C., Calderaro J., Bioulac-Sage P., Laurent C., Laurent A., Cherqui D., Balabaud C., Zucman-Rossi J.
High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions.
Nat. Commun. 4:2218.1-2218.7(2013)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=25574106; DOI=10.3748/wjg.v21.i1.311; PMCID=PMC4284350
Cevik D., Yildiz G., Ozturk M.
Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations.
World J. Gastroenterol. 21:311-317(2015)

PubMed=25877200; DOI=10.1038/nature14397
Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.
A resource for cell line authentication, annotation and quality control.
Nature 520:307-311(2015)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878
Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Genome Med. 7:118.1-118.7(2015)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

PubMed=29892436; DOI=10.1098/rsos.172472; PMCID=PMC5990783
Shioda S., Kasai F., Watanabe K., Kawakami K., Ohtani A., Iemura M., Ozawa M., Arakawa A., Hirayama N., Kawaguchi E., Tano T., Miyata S., Satoh M., Shimizu N., Kohara A.
Screening for 15 pathogenic viruses in human cell lines registered at the JCRB Cell Bank: characterization of in vitro human cells by viral infection.
R. Soc. Open Sci. 5:172472-172472(2018)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=31063779; DOI=10.1053/j.gastro.2019.05.001
Caruso S., Calatayud A.-L., Pilet J., La Bella T., Rekik S., Imbeaud S., Letouze E., Meunier L., Bayard Q., Rohr-Udilova N., Peneau C., Grasl-Kraupp B., de Koning L., Ouine B., Bioulac-Sage P., Couchy G., Calderaro J., Nault J.-C., Zucman-Rossi J., Rebouissou S.
Analysis of liver cancer cell lines identifies agents with likely efficacy against hepatocellular carcinoma and markers of response.
Gastroenterology 157:760-776(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

PubMed=31378681; DOI=10.1016/j.ccell.2019.07.001; PMCID=PMC7505724
Qiu Z.-X., Li H., Zhang Z.-T., Zhu Z.-F., He S., Wang X.-J., Wang P.-C., Qin J.-J., Zhuang L.-P., Wang W., Xie F.-B., Gu Y., Zou K.-K., Li C., Li C., Wang C.-H., Cen J., Chen X.-T., Shu Y.-J., Zhang Z., Sun L.-L., Min L.-H., Fu Y., Huang X.-W., Lv H., Zhou H., Ji Y., Zhang Z.-G., Meng Z.-Q., Shi X.-L., Zhang H.-B., Li Y.-X., Hui L.-J.
A pharmacogenomic landscape in human liver cancers.
Cancer Cell 36:179-193.e11(2019)

Cross-references
Cell line collections (Providers) ATCC; CRL-8024
BCRC; 60223
BCRJ; 0274
CLS; 300315
ECACC; 85061113
IZSLER; BS TCL 122
JCRB; IFO50069
JCRB; JCRB0406
KCB; KCB 200785YJ
KCLB; 28024
NCBI_Iran; C145
RCB; RCB1887 - Discontinued
TKG; TKG 0376
Ubigene; YC-C125
Cell line databases/resources CLO; CLO_0008458
CLO; CLO_0008459
MCCL; MCC:0000384
CLDB; cl3914
CLDB; cl3915
CLDB; cl3916
CLDB; cl5248
cancercelllines; CVCL_0485
CCRID; 1101HUM-PUMC000674
CCRID; 1102HUM-NIFDC00071
CCRID; 3101HUMTCHu119
CCRID; 4201HUM-CCTCC00644
Cell_Model_Passport; SIDM01318
CGH-DB; 9070-4
DepMap; ACH-001318
LIMORE; PLC8024
LIMORE; PLCPRF5
LINCS_LDP; LCL-1942
TOKU-E; 2898
Anatomy/cell type resources BTO; BTO:0003492
Biological sample resources BioSample; SAMN03471130
BioSample; SAMN03473236
BioSample; SAMN10988112
CRISP screens repositories BioGRID_ORCS_Cell_line; 484
Chemistry resources ChEMBL-Cells; CHEMBL3308140
ChEMBL-Targets; CHEMBL1075561
GDSC; 925349
PharmacoDB; PLCPRF5_1274_2019
PubChem_Cell_line; CVCL_0485
Encyclopedic resources Wikidata; Q54947574
Experimental variables resources EFO; EFO_0006291
Gene expression databases ArrayExpress; E-MTAB-783
ArrayExpress; E-MTAB-2706
ArrayExpress; E-MTAB-2770
GEO; GSM207051
GEO; GSM565881
GEO; GSM827153
GEO; GSM886865
GEO; GSM887520
GEO; GSM887930
GEO; GSM888602
GEO; GSM936773
GEO; GSM2551580
GEO; GSM2551581
Polymorphism and mutation databases Cosmic; 721061
Cosmic; 808505
Cosmic; 871514
Cosmic; 873402
Cosmic; 925349
Cosmic; 945155
Cosmic; 948065
Cosmic; 1019318
Cosmic; 1351513
Cosmic; 1518224
Cosmic; 2023861
Cosmic; 2162538
Cosmic; 2321033
Cosmic; 2674231
Cosmic; 2773187
IARC_TP53; 107
IARC_TP53; 30016
LiGeA; CCLE_292
Progenetix; CVCL_0485
Sequence databases EGA; EGAS00001000610
Entry history
Entry creation04-Apr-2012
Last entry update02-May-2024
Version number44